GlassScriptPhysician profile
Jeffrey D Bachtel
NPI 1013974997
$2,639.00
in general payments reported to CMS, 2019-2025
32 companies · $71.99 in 2025
The $71.99 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,174 · 2020: $541 · 2021: $12.08 · 2022: $154 · 2023: $284 · 2024: $401 · 2025: $71.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $757.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $330.05 | 2019-2024 | |
| Amgen INC. | $255.44 | 2019-2024 | Krystexxa |
| Allergan, INC. | $246.42 | 2019-2020 | |
| Glaxosmithkline, LLC. | $226.08 | 2019-2023 | Trelegy Ellipta |
| Abbvie INC. | $218.25 | 2019-2024 | Qulipta |
| Astrazeneca Pharmaceuticals LP | $136.65 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.15 | 2019-2024 | Ofev |
| Amarin Pharma, INC. | $128.52 | 2019-2020 | |
| Abbott Laboratories | $113.26 | 2022-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $106.02 | 2019-2024 | Veozah |
| Novo Nordisk INC | $102.60 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $68.41 | 2019-2020 | |
| Corcept Therapeutics | $67.57 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $65.84 | 2019-2025 | Gardasil 9, Capvaxive, Proquad |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.32 | 2022-2025 | Xifaxan |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $41.88 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $37.80 | 2019 | |
| Dexcom, INC. | $36.55 | 2023-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $30.67 | 2023 | |
| Sanofi Pasteur INC. | $28.83 | 2019 | |
| Esperion Therapeutics, INC. | $28.56 | 2020 | |
| Lilly USA, LLC | $25.77 | 2019-2023 | Mounjaro |
| Scilex Pharmaceuticals INC. | $21.11 | 2019 | |
| Shire North American Group INC | $17.39 | 2019 | |
| Ironshore Pharmaceuticals INC. | $17.00 | 2019 | |
| Xeris Pharmaceuticals, INC. | $16.99 | 2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $16.49 | 2019 | |
| Cranial Technologies, INC | $15.77 | 2023 | Doc Band |
| E.R. Squibb & Sons, L.L.C. | $13.26 | 2024 | Camzyos |
| Kowa Pharmaceuticals America, INC. | $13.17 | 2023 | Seglentis, Livalo |
| Biodelivery Sciences International, INC. | $13.10 | 2020 | |
| Almatica Pharma LLC | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Bachtel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.